Identification of cancer-related antigen based on next-generation sequencing data

Research Project

Project/Area Number	26461448
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Hematology
Research Institution	Okayama University
Principal Investigator	Kondo Eisei 岡山大学, 医歯薬学総合研究科, 講師 (30379747)
Project Period (FY)	2014-04-01 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000) Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2014: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords	腫瘍免疫 / CTL / CD40-B / 白血病 / 腫瘍抗原 / テーラーメイド抗原
Outline of Final Research Achievements	Cancer-related missense somatic mutations (so-called neoantigens) can be recognized by cytotoxic T-cell as non-self tumor antigens. We have been reported that CD40-activated B cells are efficient antigen presenting cells and can be generated from small amount of peripheral blood. We aimed to identify acute myeloid leukemia associated neo-antigens from patients treated with allogeneic stem cell transplantation. We have assessed CD8+ T cell response against neoantigen candicates from two patints with written informed consent, but failed to detect it.